Home         Infrared Laser         Meet The Team         Our Mission        Investor Relations       Breaking News       Contact Us

Copyright Medifirst Solutions, Inc  2017

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS ANNOUNCES A COMPANY UPDATE FOR ITS LASER DIVISION

 

Freehold, NJ – October 8, 2019 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared TTML-810/2000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services and Distributor of USA Premium Hemp and CBD products available at www.usacbdshopper.com is pleased to provide a company update.
 

As stated in recent announcements, one of the new areas the Company has been focusing on with its FDA cleared Infrared Laser, is to treat the side effects of cancer therapy called Oral Mucositis.  After working with an affiliate company to host three recent educational laser events, and getting very positive feedback, Medifirst plans to attend and exhibit at the Greater NY Dental Meeting November 29th to December 4th at the Jacob K. Javits Convention Center in New York City. The Company considers this a very high profile venue to present its laser for the treatment of Oral Mucositis and TMJ. Clinical studies have shown the Infrared Laser to be very effective for patients who suffer from the pain and side effects of TMJ. The Dental Meeting is considered the largest dental meeting in the United States with over 52,000 attendees. Additionally, working with an affiliate company, we anticipate several NYC dental practices to begin to offer the laser treatments for Oral Mucositis in the upcoming months.
 

In a major new development, two major healthcare providers have recently approved laser therapy billing for the treatment of Oral Mucositis. The term Photobiomodulation (the science behind the laser), we believe, is starting to become recognized as mainstream in medicine as health insurance providers and medical organizations are updating their policies and stating that (Low Light Laser Therapy, LLLT) laser treatments are accepted for Oral Mucositis. Commented Medifirst President Bruce J. Schoengood, “Having an approved CPT code is the gold standard for medical billing.  This is very exciting and positions Medifirst to present our Infrared laser to medical professionals that is billable with the proven laser technology. A business strategy we are implementing is to work with dentists, oral surgeons, ENTs, and Physical Therapists thereby expanding their medical services by offering a turn-key business model which can include our Aesthetic Laser Program called the Time Machine Program and our Head & Neck Laser Program for pain, inflammation, TMJ and Oral Mucositis.”

 

The Medifirst Infrared 810nm Laser can be used for patients who develop painful or debilitating ulcers in the soft tissues within the oral cavity.  According to industry statistics, Oral Mucositis affects roughly 400,000 patients annually in the United States, affecting their cheeks, lips, gums, inner cavity and tonsilary region which includes all of the soft tissues. Treatment options today are rather limited. Patients are usually given pain medication and/or antiseptic mouthwash. Beyond that, we believe, there's not much doctors can do for the painful condition that, at advanced stages, can inhibit a patient's ability to eat and speak.

  

About the Time Machine Laser
The Time Machine Laser is the only all-in-one, affordable, FDA cleared, Infrared, 810nm, 2000mW power, small, hand-held portable laser marketed for pain relief in the U.S.  The Time Machine Laser, which has been extensively tested and approved by Intertek for safety and electrical standards, has the power and frequency often found in large and expensive stationary units and at a fraction of the cost.  Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Lasers is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.  

 

 

 

________________________________________________

 

 

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

Medifirst Solutions Provides Company Update for Its Oral Mucositis Treatment Studies

 

Freehold, NJ – August 22, 2019 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-810/2000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services and Distributor of USA Premium Hemp and CBD products available at www.usacbdshopper.com is pleased to provide a company update.

 

Medifirst is pleased to announce that they are working with its affiliate and consulting groups in setting up a clinical trial for the treatment in reducing Oral Mucositis that will include three testing locations. Medifirst recently announced a new expansion and direction for its Time Machine Therapeutic Laser for the application of Photobiomodulation (PBM) to treat a side effect of cancer therapy called Oral Mucositis. This would involve adding a new claim and a new name for the laser treatment program via an FDA pre-submission application for the FDA 510(k) cleared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. Discussions are underway with two Universities that have expressed interest to participate. Additionally, Dr. Ronald L. Rubin DMD, an Oral & Maxillofacial Surgeon and the Medifirst Medical Director, will conduct one of the studies in his Florida practice.  Dr. Rubin, a Specialist in Head and Neck Cancer, (he was granted an American Cancer Society Fellowship in Head and Neck Cancer at the Tufts-New England Medical Center in Boston) will be setting up an IRB for the treatment protocols and is the Chief Clinical Investigator that will guide the Universities with the treatment protocols and over-seeing the clinical review. It must be noted that the Company cannot guarantee the participation of the Universities until all the details and procedures have been formulated and all terms agreed to.

 

CPT Code

It is the opinion of the Company that Photobiomodulation is becoming a mainstream treatment modality in the medical community and the FDA 510(k) cleared TTML-810/2000 Infrared laser has shown that its safety and efficiency to meet the proper guideline for a CPT approval process. Although we cannot guarantee a new code will be approved, we believe that the Time Machine TTML-810/2000 Infrared Laser, in the coming months, may receive a CPT code for specific pain treatments. CPT codes are the billing codes used for reimbursement for services and treatments by the healthcare providers.   

 

Home Study

A Medifirst affiliate partner has previously filed for a $3,000,000 grant to perform a study for home usage (OTC) for the Time Machine TTML-810/2000 Infrared Laser.  The company received the first round of comments back from the NIH grant oversite committee and will be submitting its answers back for an October review meeting date. With millions of people suffering from everyday pain, Medifirst considers “home use” a major priority if the laser can be proven safe and FDA cleared for home use. Commented CEO Bruce J. Schoengood, “FDA clearance for “home use” would potentially be one of the biggest markets we can target for our Infrared Laser.  The home treatment, as well as in Nursing Homes and Assisting Living facilities, could help people suffering from pain and provide a treatment option in the convenience of their home. Many people are not physically able to travel several times a week to a doctor’s office and it can be a financial burden as well.”  Once approved, the patient would receive a prescription and pick up the laser at their doctor’s office or medical supply store. Since the process is ongoing, Medifirst cannot, at this time,  guarantee the grant will be approved.

 

 

Medifirst anticipates further updates and details regarding these developments in the upcoming weeks and months. 

 

About Oral Mucositis

Oral Mucositis affects about 400,000 patients annually in the United States, affecting their cheeks, lips, gums, inner cavity and the tonsillar region. Treatment options today are rather limited. Patients are usually given pain medication and/or an antiseptic/anti-inflammatory mouthwash. Beyond that, there's not much doctors can do for the painful condition that, at advanced stages, can inhibit a patient's ability to eat, speak or maintain health. We believe that laser therapy can be effective in treating Oral Mucositis and the Company anticipates working with industry professionals to advance and explore using laser technology for this condition. 

 

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

 

_______________________________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS PROVIDES COMPANY UPDATE FOR ITS TIME MACHINE LASER AND CBD DIVISION

 

Freehold, NJ – August 7, 2019 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services and Distributor of USA Premium Hemp and CBD products is pleased to provide a company update.

Medifirst recently announced a possible new expansion and direction for its Time Machine Therapeutic Laser for the application of Photobiomodulation (PBM) to treat a side effect of cancer therapy called Oral Mucositis.  Medifirst is pleased to announce that they have engaged its FDA consulting firm to assist in preparing and submitting a pre-510(k) submission to the FDA for 510(k) indication for treating Oral Mucositis with its FDA 510(k) cleared hand-held Infrared 810nm Laser. The Company believes it is an area that presents very a promising usage for its 810nm Laser as patients often develop painful or debilitating ulcers in the soft tissues within the oral cavity.  According to industry statistics, Oral Mucositis affects about 400,000 patients annually in the United States, affecting their cheeks, lips, gums, inner cavity and tonsillary region. Treatment options today are rather limited. Patients are usually given pain medication and/or antiseptic mouthwash. Beyond that, there's not much doctors can do for the painful condition that, at advanced stages, can inhibit a patient's ability to eat and speak. We believe that laser therapy can be effective in treating Oral Mucositis and the Company anticipates working with industry professionals to advance and explore using laser technology for this condition.

Medifirst is pleased to announce that a leading healthcare and medical device industry report recently has included Medifirst Solutions in its industry analysis.  The report called “Aesthetic Laser - Medical Devices Pipeline Assessment, 2019” provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Aesthetic Laser pipeline products.   See https://www.researchandmarkets.com for more details.

Medifirst Solutions is pleased to announce that its USA CBD website is now live at www.USACBDshopper.com. The CBD and Hemp products includes a 500mg oil, 1000mg oil and a premium supreme 6000mg oil. In addition to the oils, also called tinctures, the company is selling CBD and Hemp Mints. Commented Medifirst President Bruce J. Schoengood, “We are very pleased to be offering high quality products that are backed by third party lab testing. According to media reports, there are many CBD products in the marketplace that do not have the CBD potency as claimed on their labels and people are purchasing expensive products that are, in our opinion, basically worthless. Our goal is to create a quality CBD and hemp brand that consumers can trust and that will be beneficial to their lives and well-being.” The company plans to launch several additional websites to support is lineup that will include several new CBD and hemp based products in development.

Medifirst anticipates further updates and announcements in the upcoming days and weeks to the Company divisions. 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

______________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

 

 

MEDIFIRST SOLUTIONS TO PROVIDE COMPANY UPDATE

Freehold, NJ – July 17, 2019 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services and Distributor of USA Premium Hemp and CBD products is pleased to provide a company update.

Medifirst Solutions previously announced that they have been approved for credit card processing for its USA PREMIUM CBD & Hemp products division. The CBD and Hemp products includes a 500mg oil, 1000mg oil and a premium 6000mg oil. In addition to the oils, also called tinctures, the company is selling CBD and Hemp Mints.

We are pleased to announce that we anticipate going live and rolling out our products within the next two weeks online at www.usapremiumcbd.com as well as several additional satellite websites to be announced. In addition, we plan to online launch sales for our Hemp products to be available on Amazon.com. Commented CEO Bruce J. Schoengood, “We are very excited to be launching our CBD line of oils and mints and we believe we have outstanding quality products all backed up by independent lab testing. In additional to our current line of oils and mints, the company plans to develop and distribute its own line of cosmetic CBD products, several new CBD liquid products and several creams and oils for pain.”

Recent industry projections forecast the CBD market to hit 16 billion dollars by 2025. Continues Schoengood, “This industry is very young and there is great interest in CBD and Hemp products.  Our mission is to develop and market high quality products that consumers can trust and all backed up by independent lab testing. “

We believe that adding high quality and some unique CBD and Hemp products to our product line is a great compliment to our therapeutic Infrared Time Machine Laser used for helping people who suffer from pain and inflammation.”

Medifirst is pleased to announce that company representatives are currently in China performing laser tests and trial treatments for a healthcare group that plans to open over 1000 pain centers across the country. In China, there is a great demand for all natural and drug-free solutions to both chronic and everyday pain and we believe our FDA cleared Time Machine 810nm Infrared laser can provide a useful and effective tool for healthcare professionals.  At this time, there is no guarantee of a final agreement and we will announce further updates as we progress.

Medifirst is also pleased to announce a possible new expansion and direction for our Therapeutic Laser. Although there are many applications and protocols for laser as related to pain and inflammation, we were most excited by the recent application of Photobiomodulation  (PBM) to treat a side effect of cancer therapy called Oral Mucositis.  This is an area that presents very a promising usage of our 810nm Laser as patients often develop painful or debilitating ulcers in the soft tissues within the oral cavity.  According to industry statistics, Oral Mucositis affects roughly 400,000 patients annually in the United States, affecting their cheeks, lips, gums, inner cavity and tonsilary region which includes all of the soft tissues. Treatment options today are rather limited. Patients are usually given pain medication and/or antiseptic mouthwash. Beyond that, there's not much doctors can do for the painful condition that, at advanced stages, can inhibit a patient's ability to eat and speak. We believe that laser therapy can be effective in treating Oral Mucositis and the Company is working with industry professionals to advance and explore using laser technology for this condition. Medifirst anticipates further updates and announcements in the upcoming days and weeks to the above mentions updates as well to our Specialty Pharma Consulting division. 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

___________________________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS GETS APPROVAL FOR MERCHANT ACCOUNT FOR HEMP AND CBD PRODUCTS  

Freehold, NJ – June 6, 2019 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services and Distributor of USA Premium Hemp and CBD products is pleased to provide an update.

Medifirst Solutions is pleased to announce that they have been approved for credit card processing for its USA CBD & Hemp products division. The CBD and Hemp products includes a 500mg oil, 1000mg oil and a premium 6000mg oil. In addition to the oils, also called tinctures, the company is selling CBD and Hemp Mints. Commented Medifirst President Bruce J. Schoengood, “We are very pleased with our initial development of CBD and Hemp products. The products under our USA line are of top premium quality and we believe, our 6000mg oil presents a unique and potent product for consumers, especially those who suffer from more severe conditions. Our Premium Mints include twenty five 10mg mints in a sturdy tin. The Mints provide a great alternative to Hemp and CBD gummies which is a very popular consumer product. We believe that our Mints are better tasting and more potent than most gummy products on the market.  Our goal is to have what we consider, the Gold Standard of CBD and Hemp products. “Products consumers you can trust” is our company mission.”

Recent industry projections forecast the CBD market to hit 16 billion dollars by 2025. Continues Schoengood, “Although there appears to be many CBD product on the market, the industry is still in its infancy. We believe that adding high quality and some unique CBD and Hemp products to our product line is a great compliment to our therapeutic Infrared Time Machine Laser used for helping people who suffer from pain and inflammation.” The company anticipates an announcement in the coming days to officially launch and introduce the USA CBD and Hemp website and product line.”

 

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

___________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS FINALIZES RELATIONSHIP WITH DR. GUPTA PHARMA

Freehold, NJ – November 28, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services, is pleased to introduce Dr. Sanjay Gupta, Chief Executive Officer of Dr. Gupta Pharma LLC and President of the American Pain Association, as the Company’s partner in its new Cannabidiol (“CBD”) division.

 

Medifirst recently announced that it has launched USA Pharma, Inc., its division for CBD distribution, sales and products and that it completed an agreement with Dr. Gupta Pharma LLC to distribute a line of premium CBD oils. Dr. Sanjay Gupta, not related to Dr. Gupta of CNN, is a Harvard-trained physician who specializes in the treatment of pain, has significant experience using Marijuana and CBD for treating pain. As the President of the American Pain Association, Dr. Gupta believes that CBD, used under the guidance of a physician, can play a significant role in reducing pain and helping to curb the opioid epidemic. Additionally, he believes CBD can play a major role in overall health and wellness but, he concedes, CBD remains underutilized as there is a substantial lack of education and stigma from public and healthcare providers with regards to the benefits of CBD. Unlike Marijuana, CBD does not produce a high and Dr. Gupta believes CBD is very safe to use. Dr. Gupta and the American Pain Association recently completed a 10-city tour to meet with governors and lawmakers regarding how to educate the public about benefits of CBD.  Dr. Gupta is a staunch supporter of CBD and is on the front-lines of bringing CBD to the mainstream medical community.  The American Pain Association is currently initiating several studies on CBD in conjunction with various prestigious Medical school faculties across North America. 


Based on his clinical and research work and using proprietary patented methods, Dr. Gupta has created CBD wellness products that he believes can benefit patients suffering from many different health conditions. Today, Medifirst President Bruce J. Schoengood, stated that “We are thrilled to be working with Dr. Gupta and look forward to distributing and participating in a CBD product line that, we believe, can be of great help as an all-natural product to battle pain as well as the opioid crisis. The Dr. Gupta CBD product line, we believe, will have great interest and demand by physicians and the medical community, in addition to producing unrivaled quality products for consumers.” The Company is expected to provide details about its new CBD division and the distribution agreement entered into with Dr. Gupta Pharma LLC in a Current Report on Form 8-K.

 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS ANNOUNCES NEW AGREEMENT FOR CBD PRODUCTS AND DISTRIBUTION

Freehold, NJ – November 21, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services is pleased to announce an update regarding its new cannabidiol (“CBD”) division.

Medifirst is pleased to announce that it has launched a majority-owned subsidiary USA Pharma, Inc., a division for its CBD distribution, sales and products. Medifirst is also pleased to announce it has completed an agreement with Dr. Gupta Pharma LLC to distribute a line of premium CBD oils. Dr. Sanjay Gupta, its Chief Executive Officer, not related to Dr. Gupta of CNN, is a physician who specializes in the treatment of pain, and is the President of the American Pain Association. Dr. Gupta has created his own line of CBD products that, Medifirst believes, is superior in quality and production process to any CBD product in the industry. Today, Medifirst President Bruce J. Schoengood, stated that “We believe that the CBD products in Dr. Gupta’s product line will have great interest and demand by physicians and the medical community, in addition to producing unrivaled quality products for consumers.” The company plans to release further detail regarding this agreement within days of this announcement.

There is already a great demand for all natural and drug free products for relieving pain, anxiety, stress and many other ailments and conditions. CBD is widely believed to have great medicinal value and potential. 

 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

________________________________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS ANNOUNCES NEW DIVISION FOR CBD PRODUCTS

Freehold, NJ – October 29, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and Specialty Pharmacy Drug Consulting Services is pleased to announce a company update.

Medifirst is pleased to announce that it is launching a division for CBD sales and products. There is already an explosive demand for CBD products, including healthcare and medical products, beverages and edibles, and pet products. CBD usage is surging in the United States as awareness and access to CBD products rapidly expands. CBD oil is gaining momentum with studies confirming that it may help treat a variety of ailments and conditions, such as pain, anxiety, stress, depression, cancer related symptoms, and weight loss.

The Brightfield Group recently announced projections for the hemp CBD industry to become a $5.7 billion market by next year, with a projection of nearly 400% growth to $22 billion by 2022. Hemp is variety of the cannabis plants. It does not contain any legally significant quantities of tetrahydrocannabinol (THC), the chemical that produces a high in marijuana. It does contain the active ingredient cannabidiol (CBD), which has been widely reported and shown to have great medicinal value - reports that now have been substantiated by the U.S. Food and Drug Administration. There has been a strong movement to make CBD products legal in all 50 states.

 

Today, Medifirst President Bruce J. Schoengood, stated that “CDB products are a great complement to our FDA cleared Time Machine Therapeutic Laser for all natural pain relief, and there is a tremendous demand for CBD products. Through our existing healthcare relationships, we have strong interest from oversea markets for China, Japan, and the Asia-Pacific region as well as in the U. S. market. Medifirst is working on completing related contracts and agreements and anticipates a formal announcement in the upcoming days and weeks.”

 

Medifirst recently announced it was presenting the Time Machine Laser to the Antah HealthCare Group, one of the largest medical device distributors in Malaysia. Medifirst President, Bruce J. Schoengood, stated that, “We are very pleased to report that initial testing results are positive and Medifirst representatives are meeting with Antah representatives in Hong Kong to discuss possible distribution structures and various possible business models with regards to working with Antah Healthcare. While we can make no assurances of a final agreement, we are optimistic since they are satisfied with the results. We anticipate further updates in the upcoming days and weeks.”

About CCRx

CCRx services of specialty drug pharmacy consulting and revenue stream management utilizes over 60 years of combined specialty pharmacy and infusion therapy experience. The services are designed to increase profits for pharmacies.  Services include: clinical review, expedited medical insurance verification, training for drug dispensing, insurance billing, collections, and reconciliation. The billing services will address any denials and include appeals and resubmissions. The division will provide key services to undervalued clients by securing reimbursement of overlooked revenue within the ever-expanding
market of the specialty pharmacy market in today's healthcare system.

 

Specialty drugs, often described as prescription drugs that are difficult to manufacture and require special handling or administration, have limited distribution, target a narrow group of chronic diseases, are costly, and require ongoing clinical support, we believe, will drive nearly all the pharmaceutical industry’s market growth from 2015–2020.

 

 Industry analysts projects the total pharmaceutical industry to exceed $483 billion in 2020, with specialty pharmaceuticals making up 44% of the revenue. If these projections hold true, specialty drugs will have increased their revenues by over 5X from 2010–2020, growing from just 15% of the market to nearly half in that decade.

 

About The Time Machine Laser

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

________________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS ANNOUNCES UPDATE FOR ITS TIME MACHINE LASER DIVISION

 

Freehold, NJ – August 23, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and Specialty Pharmacy Drug Consulting Services is pleased to announce an update for its laser division.

 

Medifirst is pleased to announce that they have been working with the Antah HealthCare Group and Fullerton Health to introduce the Time Machine Laser as a drug-free and natural treatment for pain and inflammation. Antah HealthCare Group is one of the largest Malaysian owned healthcare marketing and distribution companies in Malaysia. They have over 250 employees with branch offices located at major cities nationwide. The group has over 50 years of experience in the healthcare industry. Additionally, Fullerton Health is in the process of testing the Time Machine Laser at its Singapore facilities.  Fullerton Health is a leading vertically integrated healthcare platform in the Asia Pacific region. Founded in Singapore in 2011, they own and operate an extensive network of healthcare facilities across 8 countries and partner with established and reputable healthcare providers in the region.  As a pioneer of healthcare innovation, they leverage technology to provide cost-effective management and administration of healthcare services. Commented Medifirst President, Bruce J. Schoengood, “We are very pleased and excited to be working with such established healthcare leaders and introduce our laser to the Asia Pacific market. Both companies are committed to seeking drug free and natural pain solutions that effect tens of thousands of lives. Although definitive agreements have not been finalized, we are very optimistic about our progress and the enthusiasm of these healthcare companies with regards to our laser. We anticipate further announcements in the upcoming days and weeks.”

 

NAALT 2018 CONFERENCE
North American Association for Photobiomodulation Therapy


This past week, our V.P and Medical Director, Dr. Ronald Rubin was invited and honored to speak and introduce The Time Machine Laser at this prestigious conference.  The NAALT 2018 conference focus was Photobiomodulation and Drug-Free Management of Pain with the emphasis on treatment of pain and the acceleration of tissue healing.

As been widely reported, President Trump has declared a State of Opioid Emergency. A public health emergency exists, and it is our belief, that laser technology can provide a viable pain treatment solution that is drug-free. The purpose of NAALT is to be a forum for therapeutic light therapy practitioners in North America (Mexico, USA and Canada), as well as many other countries that attended the conference. Its goal is to promote phototherapy as a valid treatment, and to improve understanding of photobiological mechanisms, basic therapeutic light physics, safety, treatment parameters, techniques, regulatory issues and reimbursement. Panels of researchers and clinicians from around the world gathered together to share their research and clinical experience in the effective drug-free management of pain.

Commented Dr. Rubin, “This was an amazing opportunity to introduce our Time Machine Laser device to such leading and esteemed experts including Dr. Michael Hamblin, of the Wellman Center for Photomedicine, a teaching Affiliate of the Harvard Medical School. Dr. Hamblin is widely recognized as the leading expert in low light laser therapy and photobiomodulation.  I was delighted to meet colleagues from around the world and I am confident that this conference will lead to many new opportunities for Medifirst and the Time Machine Laser.”

About CCRx

CCRx services of specialty drug pharmacy consulting and revenue stream management utilizes over 60 years of combined specialty pharmacy and infusion therapy experience. The services are designed to increase profits for pharmacies.  Services include: clinical review, expedited medical insurance verification, training for drug dispensing, insurance billing, collections, and reconciliation. The billing services will address any denials and include appeals and resubmissions. The division will provide key services to undervalued clients by securing reimbursement of overlooked revenue within the ever-expanding
market of the specialty pharmacy market in today's healthcare system.

 

Specialty drugs, often described as prescription drugs that are difficult to manufacture and require special handling or administration, have limited distribution, target a narrow group of chronic diseases, are costly, and require ongoing clinical support, we believe, will drive nearly all the pharmaceutical industry’s market growth from 2015–2020.

 

 Industry analysts projects the total pharmaceutical industry to exceed $483 billion in 2020, with specialty pharmaceuticals making up 44% of the revenue. If these projections hold true, specialty drugs will have increased their revenues by over 5X from 2010–2020, growing from just 15% of the market to nearly half in that decade.

 

About The Time Machine Laser

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

________________________________________

 

 

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS ANNOUNCES NEW CONSULTING AGREEMENT FOR ITS SPECIALTY DRUG DIVISION

 

 

Freehold, NJ – August 2, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology and specialty pharmacy drug and consulting services is pleased to announce that Concierge Concepts Rx (CCRx), a division of Medifirst Solutions, has signed an exclusive three-year Specialty Pharmacy Consulting Agreement with QuickChek, a New Jersey based company that owns 153 convenience stores including pharmacy services. They have 4000 employees in New Jersey and New York locations.

 

As part of the agreement, CCRx will provide consulting services to QuickChek pharmacies so they can enter and participate in the ever-expanding market of specialty drugs.  CCRx will provide services that include: clinical review, expedited medical insurance verification, training for drug dispensing, insurance billing, collections, and reconciliation. The billing services will address any denials and include appeals and re-submissions.

 

Commented CCRx President Walter Molokie, “We plan to bring in new business and revenue streams to the QuickChek line of pharmacies and develop as well as implement a new sales strategy to generate sales for specialty drugs. We are excited and very pleased to be working with QuickChek, a company of great quality and outstanding service to the community. Additionally, we are very confident that our strategy to expand their pharmacy services will result in increased revenues. Commented Medifirst President Bruce J. Schoengood, “We believe CCRx, with its focus on specialty drugs, can provide great growth for Medifirst as well as open up many doors for new related opportunities. Many companies have been contacting CCRx to inquire about its services and expertise and we anticipate additional announcements and further updates on QuickChek in the upcoming days and weeks.”

 

About CCRx

CCRx services of specialty drug pharmacy consulting and revenue stream management utilizes over 60 years of combined specialty pharmacy and infusion therapy experience. The services are designed to increase profits for pharmacies.  Services include: clinical review, expedited medical insurance verification, training for drug dispensing, insurance billing, collections, and reconciliation. The billing services will address any denials and include appeals and resubmissions. The division will provide key services to undervalued clients by securing reimbursement of overlooked revenue within the ever-expanding
market of the specialty pharmacy market in today's healthcare system.

 

Specialty drugs, often described as prescription drugs that are difficult to manufacture and require special handling or administration, have limited distribution, target a narrow group of chronic diseases, are costly, and require ongoing clinical support, we believe, will drive nearly all the pharmaceutical industry’s market growth from 2015–2020.

Industry analysts projects the total pharmaceutical industry to exceed $483 billion in 2020, with specialty pharmaceuticals making up 44% of the revenue. If these projections hold true, specialty drugs will have increased their revenues by over 5X from 2010–2020, growing from just 15% of the market to nearly half in that decade.

 

About The Time Machine Laser

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

_______________________________________

FOR IMMEDIATE RELEASE
Contact:    Investor Relations
Phone:       (732) 786-8044
Email:        admin@medifirstsolutions.com
Website:    www.medifirstsolutions.com


MEDIFIRST SOLUTIONS  ADDS A NEW MODEL TO ITS TIME MACHINE INFRARED LASER SERIES

 


 

 

 

 

 

 

 

 

 

 

 

Freehold, NJ – August 18, 2017 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce that it has added a white model to its Infrared Time Machine Laser.
 
Commented CEO, Bruce J. Schoengood, “The company continues to develop its Laser Series and is adding a sleek white model which provides a cutting-edge yet traditional look to the laser. As we work to solicit hospitals and medical centers throughout the world, it is our opinion that the look of the laser is an important factor in introducing the laser. Now we can offer the medical community a choice of our two models.”  In addition to adding the white model, the Time Machine Laser engineers are working on the next generation Time Machine Laser which will transition from push button to a full touch screen with extensive built-in programming. Continued Schoengood, “Although we are just entering the market and introducing our laser, it is imperative we keep product development a top priority as we continue to work to offer cutting-edge technology at an affordable price. It is our belief that with the opioid crisis reaching epidemic proportions in the US and throughout the world, our laser can provide relief and support to medical professionals who are on the front lines of this battle.”


This past weekend we visited NFL player Jordan Poyer of the Buffalo Bills at his training camp. As recently announced, Jordan is fully committed to endorsing the Time Machine Laser, not just to professional athletes, but to the world. He understands that crisis we are all facing in fighting pain and addiction and he is passionate to help us get the word out about the Time Machine Laser. Jordan was referred to the Time Machine Laser Program for treatments to help relieve pain in his shoulder and ankle resulting from the intense training regiments common for NFL players.  Commented Mr. Poyer, “After a single treatment, I feel instant relief and actually see swelling going down. I love what the Time Machine Laser has to offer and I am proud to be working with Medifirst to introduce its treatment capabilities to fellow athletes and medical staff.  I truly want to help spread the word that there are alternative treatment solutions out there that avoid or reduce the need to pop pain pills or to take pain injections.  The Time Machine Infrared Laser is completely mobile and portable and needs to be used on the sidelines and in locker rooms of all professional sports.”


An interesting development recently announced by the NFL is that they are seeking to explore the use of medical marijuana for NFL players. According to the Washington Post, the NFL has sent a letter to the NFL Players Association (NFLPA) offering to work together on a study looking at the potential use of medical marijuana as a pain management tool. Medifirst and its Laser Series seeks to be part of the solution.

Medifirst notes that the relationship with Jordan Poyer is in no way and in no manner an endorsement by or relationship with the National Football League (NFL) or any of its affiliates or franchises, including the Buffalo Bills.
 

 

About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.
 
#  #  #
Forward-Looking Statements:  

The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.


 __________________________________________________________________________________________________________________

 

 

FOR IMMEDIATE RELEASE

Contact:           Investor Relations
Phone:             (732) 786-8044
Email:              admin@medifirstsolutions.com
Website:          www.medifirstsolutions.com

 

 

MEDIFIRST APPOINTS EXECUTIVE ADVISOR FOR CHINA

 

 

Freehold, NJ – August 8, 2017 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce the appointment of Mr. Colin Wu to its Advisory Board. Mr. Wu will serve as the Executive Advisor to CEO Bruce J. Schoengood for matters pertaining to the China market.

 

Stated CEO Bruce J. Schoengood, “We are honored and excited to have Mr. Wu join our company as a key advisor. He is a business leader in China with decades of vast experience. We are confident that Colin’s leadership and passion for our laser technology will prove invaluable as Medifirst implements its strategy to expand to the China healthcare market. The appointment of Mr. Wu is further validation of Medifirst’s commitment to become a key player in the laser healthcare marketplace.  Treating acute and chronic pain is a big concern in China, a country of 1.4 billion people, with an aging population. Currently, their primary pain treatments are limited to pain patches and prescription medications and we believe they are very much in need of new all natural pain treatments.” 

 

Mr. Wu is executive vice chairman of the Board of Directors at US China Business Association (USCN). In his executive role, Mr. Wu is responsible for building and expanding USCN’s relationships with key strategic partners, including financial institutions, business sectors, governmental and educational entities, and he is a member of USCN’s strategic planning and development team.  

 

Mr. Wu has extensive knowledge in diplomacy, government procurement, intellectual property, history, language and arts. It has built him into a visionary with business acumen. His personal contacts with celebrities, executives of fortune 500 companies and hi-level government officials prove to be valuable assets to any projects and organizations he is committed to undertake. Because of his dedication to global business and technology leadership, he won the prestigious “Ronald Reagan Presidential Award” in 2004. Mr. Wu was elected to serve in 2005 as honorary co-chairman of the Business Advisory Council of the National Republican Congressional Committee. 

 

Mr. Wu set up online government procurement service website Bid8.com in 2000 and served as CEO of the company. Under his leadership, Bid8.com grew to be a multi-billion dollar online procurement platform and a recognized market leader in government procurement information, a concept the company pioneered. Mr. Wu led the company’s successful merger with FedBizOpps.gov in 2009. 

 

In 2007, Mr. Wu was invited by Yiwu Government to implement their economic policy of “Selling to the World, Buying from the World”. Mr. Wu effectively helped them set up Imported Commodities Market at the Yiwu Small Commodities Market within short deadline via his global procurement network, thus changing the landscape of Yiwu as a distribution hub of exclusive Chinese commodities to commodities from all over the world.

 

In 2009, Mr. Wu teamed up with Shenzhen United Property and Share Rights Exchange to launch an Intellectual Property Exchange—Shenzhen Innovated Technology Property Rights Exchange, a trading platform based on trading instruments of global technologies and patents, and with Chinese manufacturing sectors as its target market. Wu was instrumental in setting up Hong Kong Intellectual Property Exchange (HKIPX) and became the Chairman of the HKIPXin 2011. In 2014, Wu became a director of Zondine Property Investment LLC., introducing real estate investment opportunities in the US to the Chinese market.

 

Prior to 1989, Mr. Wu was a veteran diplomat of Foreign Affairs Ministry of the People’s Republic of China, where he served as a senior translator for Chinese and foreign state leaders.  

 

Mr. Wu holds a bachelor degree in English language and literature from Shanghai University of International Studies, and associate certificate from Beijing Foreign Affairs College. In 1994, Mr. Wu got his master degree in History at Eastern Illinois University. In 1993-1994, he studied for his second master degree of Arts Management at University of Illinois. 

 

About Medifirst Solutions, Inc.

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 

#  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

___________________________________________________________________________________________________________________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS ANNOUNCES COMPANY UPDATE

Freehold, NJ – July 24, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology and specialty pharmacy drug and management consulting services is pleased to announce a shareholder update.

  

As recently announced, Concierge Concepts Rx (CCRx), a new division of Medifirst Solutions will provide a unique niche billing and specialty drug consulting service to independent pharmacies who are struggling to maintain profitability as well as regional chains and supermarket pharmacies seeking to incorporate specialty drugs.

 

As part of adding this very exciting division to Medifirst, the company has worked with the management of CCRx to drive various operational developments.  Medifirst believes that it has driven past the ‘proof of concept’ stage of CCRx’s development and that it is in the best interest of the company to further align the interests of CCRx’s management with that of Medifirst.  Accordingly, on July 23, 2018, Medifirst effectuated a corporate action that sets the foundation for a new capital structure to support CCRx’s growth through strategic partners and co-venture opportunities within the industry. 

 

Commented Medifirst President Bruce J. Schoengood, “Since inception, Medifirst has never initiated a capital restructure but we believe that, with the addition of CCRx and the opportunities in the specialty drug sector, Medifirst can significantly benefit and bring much greater value to the company and its shareholders.”

 

The Company plans to make a formal announcement and provide more details in the upcoming days.

 

 

About CCRx

CCRx services of pharmacy consulting and revenue stream management, utilizing over 60 years of combined specialty pharmacy and infusion therapy experience, seek to increase profits for these pharmacies.  Our contracting services will include: sales, patient care, operations, and navigation of the complex landscape of major medical insurance billing. The division will provide key services to undervalued clients by securing reimbursement of overlooked revenue within the ever-expanding market of the specialty pharmacy market in today's healthcare system.

 

CCRx is dedicated to expanding retail pharmacy into the emerging Specialty Pharmacy market and opening revenue streams to promote market competitiveness and profitability. Expertise includes: Specialty and infusion pharmacy consultants, billing expertise for Specialty Pharmacy products, third party billing provider and services, authorization analysis, experts with 60 years of combined specialty pharmacy and infusion therapy management.

Specialty drugs, often described as prescription drugs that are difficult to manufacture and require special handling or administration, have limited distribution, target a narrow group of chronic diseases, are costly, and require ongoing clinical support, will drive nearly all the pharmaceutical industry’s market growth from 2015–2020.

Industry analysts projects the total pharmaceutical industry to exceed $483 billion in 2020, with specialty pharmaceuticals making up 44% of the revenue. If these projections hold true, specialty drugs will have increased their revenues by over 5X from 2010–2020, growing from just 15% of the market to nearly half in that decade.

 

About The Time Machine Laser

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS LAUNCHES SPECIALTY PRESCRIPTION BILLING AND PHARMACY SOLUTIONS DIVISION

Freehold, NJ – May 17, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce that it has launched a new division to the company.

  

As recently announced, Concierge Concepts Rx (CCRx), a new division of Medifirst Solutions, will provide a unique niche billing service to independent pharmacies who are struggling to maintain profitability. Medifirst is pleased to announce that Walter Molokie, RPh has joined the company as CEO of CCRx. Graduate of Long Island University, his expertise is in Specialty Pharmacy and Home Infusion.  His background includes: Adjunct Professor of Alternate Site Pharmacy Practice-LIU, Regional Vice-President of Operations for Kabafusion, a national provider of Specialty Pharmacy and Home Infusion, Director of Pharmacy for Option Care, a Walgreens Company, Manager of Specialty Pharmacy for Direct Script, a wholly owned division of Oxford Health Care and Founder and President of Total Home Health Care.

 

Commented Medifirst President Bruce J. Schoengood, “We are very excited to have Walter join Medifirst. He brings decades of experience and expertise to Medifirst and CCRx. Our Time Machine Infrared Laser is product driven which requires a purchaser to be a healthcare professional that can understand and see the benefits of our laser technology, and we believe Walter will be a great ambassador of our laser product. CCRx offers pharmacies increased revenue via business and billing solutions at no cost or expense to them.” Continued Schoengood, “This business diversification, we believe, will add great value to the company. It adds a balance of both products and services that fit very comfortably within the Company’s business strategy.” 

 

 CCRx services of pharmacy consulting and revenue stream management, utilizing over 60 years of combined Specialty Pharmacy and Infusion Therapy experience, seek to increase profits for pharmacies.  Our contracting services will include: sales, patient care, operations, and navigation of the complex landscape of major medical insurance billing. The CCRx division will provide key services to undervalued clients by securing reimbursement of overlooked revenue within the ever-expanding market of the specialty pharmacy market in today's healthcare system.

 

 Specialty drugs, often described as prescription drugs that are difficult to manufacture and require special handling or administration, have limited distribution, target a narrow group of chronic diseases, and require ongoing clinical support. We believe that CCRx has the experience and expertise in Specialty Pharmacy and Infusion Therapy that many professional do not have. Industry analysts projects the total pharmaceutical industry to exceed $483 billion in 2020, with specialty pharmaceuticals making up 44% of the revenue.

About Medifirst Solutions, Inc.

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

_____________________________________________________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS TO UPDATE SHAREHOLDERS

 

Freehold, NJ – May 14, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce a shareholder update.

 

Medifirst is pleased to announce that it launched a new division which will provide a unique niche billing and medical consulting service to independent pharmacies who are struggling to maintain profitability. Our services of pharmacy consulting and revenue stream management, utilizing over 60 years of combined specialty pharmacy and infusion therapy experience, seek to increase profits for these pharmacies.  Our contracting services will include: sales, patient care, operations, and navigation of the complex landscape of major medical insurance billing. The division will provide key services to undervalued clients by securing reimbursement of overlooked revenue within the ever-expanding market of the specialty pharmacy market in today's healthcare system.

The Company plans to make a formal announcement provide more details in the upcoming days.

 

Medifirst is pleased to announce that its Medical Director, Dr. Ronald Rubin, has been selected to present his Time Machine Laser Clinical Study at the premiere annual conference for Therapeutic Light Therapy practitioners in North America (Mexico, USA and Canada). Commented Medifirst President Bruce J. Schoengood, “This is a great honor and opportunity for Medifirst to present its technology directly to some of the most esteemed medical professionals in the medical profession as well as to the medical community.”

 

The Company plans to make a formal announcement and provide more details in the upcoming days.

 

About Medifirst Solutions, Inc.

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

_________________________________________________________________________________

 

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS ANNOUNCES THE LAUNCH OF A NEW DIVISION FOCUSING ON SPECIALTY PRESCRIPTION BILLING AND PHARMACY SOLUTIONS

Freehold, NJ – April 10, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce that it is adding a new  division to the company.

  

CCRx, a new division of Medifirst Solutions launching May 1, 2018, will provide a unique niche billing service to independent pharmacies who are struggling to maintain profitability. Our services of pharmacy consulting and revenue stream management, utilizing of over 60 years of combined specialty pharmacy and infusion therapy experience, will increase profits for these pharmacies by contracting our services which will include: sales, patient care, operations, and navigation of the complex landscape of major medical insurance billing. CCRx will provide key services to undervalued clients by securing reimbursement of overlooked revenue within the ever-expanding market of the specialty pharmacy market in today's healthcare system.

 

CCRx is dedicated to expanding retail pharmacy into the emerging Specialty Pharmacy market and opening revenue streams to promote market competitiveness and profitability. Expertise includes: Specialty and infusion pharmacy consultants, billing expertise for Specialty Pharmacy products, third party billing provider and services, authorization analysis, experts with 60 years of combined specialty pharmacy and infusion therapy management.

 

Commented Medifirst President Bruce J. Schoengood, “We are very excited to be adding a medical service business to Medifirst. Our Time Machine Infrared Laser is product driven which requires a purchase by the healthcare professionals to see the benefits of our laser technology. CCRx, lead by experienced pharmaceutical specialists offers pharmacies increased revenue via business and billing solutions at no cost or expense to them. Continued Schoengood, “This business diversification, will believe, will add great value to the company. It adds a balance of both products and services that fit very comfortable within the Company.”  

 

Specialty drugs, often described as prescription drugs that are difficult to manufacture and require special handling or administration, have limited distribution, target a narrow group of chronic diseases, are costly, and require ongoing clinical support, will drive nearly all the pharmaceutical industry’s market growth from 2015–2020.

Industry analysts projects the total pharmaceutical industry to exceed $483 billion in 2020, with specialty pharmaceuticals making up 44% of the revenue. If these projections hold true, specialty drugs will have increased their revenues by over 5X from 2010–2020, growing from just 15% of the market to nearly half in that decade.

 

More details will be announced in the upcoming days and weeks.

 

About Medifirst Solutions, Inc.

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

______________________________________

 

 

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS ANNOUNCES AN UPDATE FOR CHINA DISTRIBUTION

 

 

Freehold, NJ – March 12, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce a distribution update.

Medifirst recently announced that it was in negotiations to bring its FDA cleared Time Machine Laser to the China Market. As a result of its recent addition of Life Science Quest, a medical device business development consulting firm, and the efforts and expertise of its founder Ruobing Xia, Medifirst met with a very prominent China-based medical organization to initiate negotiations for a business venture that will involve exclusive rights to sell the Time Machine Laser for the entire country of China.  

Medifirst is pleased to announce that it has signed a non-binding Letter of Intent with Beijing Long Tan Lake Sports Industry (BLTS) and Investment Development LLC based in Beijing China for a five-year exclusive distribution agreement, including a 10,000 unit order for the first year of the agreement.  To maintain exclusive rights for China, BLTS will be required to maintain a minimum unit order for the duration of the agreement.  BLTS has agreed to register and complete all necessary filing for the CFDA (Chinese FDA) necessary to initiate sales for a medical device in China.  While no assurances can be made, both parties have agreed to continue the process of due diligence and Medifirst hopes to complete a definitive agreement in the upcoming days or weeks at which time the Company will release further details.

Founded in July 2007, Beijing Long Tan Lake Sports Industry and Investment Development LLC., established an industry alliance between the sports industry and the medical industry. BLTS provided platforms, services, and assurances for collaborations between the two industries, in compliance with government policies. In collaboration with the local government, BLTS also founded Beijing Long Tan Lake Sports Industry Park in 2008. The industry park successfully merged into Zhongguancun Dongcheng Science Park by the Dongcheng district governments in 2012. The park has attracted over 2,000 registered enterprises, becoming the center of the sports and medical industry. BLTS has continued to establish collaborations with a growing network of major medical institutions including: Peking University Hospital, Peking University Third Hospital, 301 Hospital, China- Japan Friendship Hospital, An Ding Hospital, Guang’anmen Hospital, Beijing Jishuitan Hospital, Liaoning Medical University, Chongqing Medical University, Xi'an Jiaotong University Hospital. “We hope to introduce innovative medical devices to the Chinese market as part of our business expansion to establish a strong foundation in future developments in the medical industry,” said Mr. Jiang, the CEO of BLTS.

Medifirst anticipates further announcements in the upcoming days and weeks on additional company developments. 

 

About Medifirst Solutions, Inc.

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

About Medifirst Solutions, Inc.

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

______________________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS TIME MACHINE LASER TO BE USED IN SLEEP APNEA PROGRAM    

 

Freehold, NJ – February 23, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce that its Time Machine Infrared Laser will be used for a new Sleep Apnea program.

Dr. Glenn A. MacFarlane D.M.D., based in New Jersey, will use the Time Machine Infrared Laser as part of his treatment protocol for his Sleep Apnea Silent Sleep Rx program that is affiliated with many prominent healthcare centers and private practices.

Dr. MacFarlane is very passionate about Holistic Dentistry and he will be hosting educational training events on Holistic Dentistry. These events will feature Sleep Apnea education and introduce his Silent Sleep Rx program which includes the Time Machine Infrared Laser and training courses. Dental professionals throughout the country can join the network and implement the Silent Sleep Rx program and the Time Machine Laser into their practice. The benefits are new revenue streams and effective holistic treatment modalities and solutions to better serve their patients.  Dr. MacFarlane’s practice located in Red Bank, NJ includes the Time Machine Laser treatments for TMD.

Sleep disorders, including Sleep Apnea, have become a significant health issue in the United States. It is estimated that 42 million Americans suffer from Sleep Apnea, with 80 percent of the cases of moderate and severe obstructive Sleep Apnea undiagnosed. Many lawmakers are proposing legislation to have state and federal transit workers and truck drivers tested for this disorder. Recently, the National Transportation Safety Board reported that the probable cause of the 2016 NJ Transit crash at the Hoboken rail terminal, in which a train accelerated as it was coming into the station, was “the engineer’s fatigue resulting from his undiagnosed severe obstructive sleep apnea.”

 

Dr. MacFarlane is an aesthetic focused dentist, and has been dedicated for almost 30 years now, to brightening thousands of smiles. He has memberships in several prestigious organizations including the American Dental Association (national, state and county), the Academy of General Dentistry, the American Academy of Cosmetic Dentistry, the Academy of Laser Dentistry, the American Academy of Facial Esthetics, the Academy of Comprehensive Esthetics, the American Academy of Implant Dentistry and the American Academy of Dental Sleep Medicine.

 

Medifirst anticipates further announcements in the upcoming days and weeks on additional company developments which will include updates on blockchain technology and new expanding services. 

 

About Medifirst Solutions, Inc.

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

 

 

_______________________________________________

 

 

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

MEDIFIRST SOLUTIONS ANNOUNCES A BUSINESS UPDATE

 

Freehold, NJ – February 16, 2018 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce a business update.

Medifirst recently announced that it was in negotiations to bring its FDA cleared Time Machine Laser to the China Market. With the recent addition of Life Science Quest, a medical device business development consulting firm, and the efforts and expertise of its founder Ruobing Xia, Medifirst will be meeting with a very prominent China-based medical organization to complete negotiations for a business venture that will involve exclusive rights to sell the Time Machine Laser for the entire country of China.  While no assurances can be made that the Company will complete an agreement when they meet in the upcoming weeks, the Company is pleased that after initial negotiations, the medical organization from China will be flying in for a scheduled meeting in New York with intentions to set forth the terms of an agreement with Medifirst. Commented Medifirst’s President, Bruce Schoengood, “We are very excited to meet with a company that has close business relationships with many of China’s leading hospitals and medical organizations. Both parties believe that there is a huge market with great potential and a great need for all-natural pain treatments such as the Time Machine Laser for use in the China medical community.”

The Company recently presented its Infrared Laser at the Greater New York Dental Meeting held in the Jacob Javits Center. The Time Machine Laser has shown effective and immediate results for patients suffering from pain related to their temporomandibular joint (TMJ). We believe TMJ treatment provides Medifirst with a very strong, untapped, niche application for dental practitioners. Medical professionals are looking for safe alternative means of treating TMD/TMJ pain without harmful drugs or surgery. Medifirst and the Time Machine Laser has developed pain management programs for people suffering from TMJ.

TMD/TMJ dysfunction patients have been the scourge and struggle of most dentists. Due to their pain and trismus (lock jaw), the patients cannot cooperate while dentists take their dental impressions. This prevents an accurate impression of the needed inter-cuspal relationships to fabricate functional bite splints and restorations. We believe that the Time Machine Laser provides a solution. Our FDA cleared TTML Infrared Laser is able to reduce TMD pain rapidly, and without drugs. This is a major benefit for the doctors and their patients. Most often, after just one session, patients usually have as much as a 50% decrease in pain, and as it breaks the muscle spasm, the trismus is often decreased up to one cm or more. The patient is now relaxed and pain free and the dentist can proceed to making the most successful bite splits, appliances and dental reconstructions possible. We believe TMJ treatment provides Medifirst with a very strong, untapped, niche application for dental practitioners.

Medifirst is pleased to announce that it currently has five dental centers using the Time Machine Laser for TMJ pain and disorders. The company believes that these centers will serve as a model for growth and further applications of the lasers for the entire dental community. The Infrared Laser has recently been incorporated into the treatment protocols for a new major cutting-edge Sleep Apnea Program designed to treat patients in a less intrusive and more comfortably manner than the airway pressure machines with a variety of breathing masks which are the most widely used treatment for moderate and severe Sleep Apnea.  Congress has been proposing legislation for city and states to test and treat transit workers, train engineers and truck drivers for Sleep Apnea as recent studies show that many workers suffer from this sleep disorder which can be the cause of accidents. Medifirst believes its Time Machine Laser will play a vital role in the treatment of Sleep Apnea. Medifirst is also considering a rental model which will include a Time Machine Laser marketing program directed to the dentists and specialists who use the laser. With this payment model, Medifirst will continue to have recurring monthly revenue and offer doctors the added value of driving new patients and business to their practice.

Medifirst anticipates further announcements in the upcoming days and weeks on additional company developments. 

 

About Medifirst Solutions, Inc.

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

Forward-Looking Statements

The statements in this press release that relate to the company’s expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

 

 

 

_________________________________________________

 

FOR IMMEDIATE RELEASE

Contact:           Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

 

 

 

MEDIFIRST SOLUTIONS ANNOUNCES AGREEMENT WITH LIFE SCIENCE QUEST, LLC.

 

 

 

Freehold, NJ – December 14, 2017 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce it has signed an agreement with Life Science Quest, LLC.

 

Life Science Quest helps businesses to promote innovative technology, unlock global market potential, and empowers their overall growth.  Life Science Quest, with experience and resources across a broad spectrum of fields in health care and life sciences, provides high quality, results-oriented services to help businesses overcome barriers and maximize their potential.  Commented Medifirst President Bruce J. Schoengood, “We are very pleased to be working with Ruobing Xia and a company of great stature, resources and outreach that believes in our Time Machine Laser technology and its potential for US and global commercialization. Life Science Quest has a vast amount of experience working in the medical and healthcare industry including an emphasis on medical devices. Commented Ruobing Xia Co-founder of Life Science Quest, “We are excited to be working with Medifirst and its team to bring new solutions for pain treatment for patients in need. We believe that there is a great opportunity for the company to expand in the global medical laser market, especially in China, where we have successful experiences helping innovative companies to grow. With the rapidly developing and growing Chinese medical device and healthcare market, a population of 1.4 billion, and millions of patients suffering from acute and chronic pain, we think it’s time to introduce the Time Machine Laser as a new solution.”

 

Ruobing Xia bring a lifetime of experience to this project. As founder of Life Science Quest, Ruobing Xia oversees global strategy, business development, and commercial operations. Her passion to help patients by leveraging latest science and technology, guide the focus of Life Science Quest team to bring creative solutions for innovative companies to expedite their growth and deliver better products and services. In addition, Ruobing is board members of several successful startups where she is advised on the global strategy, business development, and commercial operations. Previously, she had a progressive career with Eli Lilly and Boehringer Ingelheim where she managed hundred-million-dollar product launches and promotional budgets, developed sales and marketing strategies, and generated licensing deals. This was supported by her earlier career in foreign trade, international banking, finance, and venture development. Ruobing holds Masters degrees in International Affairs (finance) from Columbia University in New York City and Business Administration (MBA) from IMD in Lausanne, Switzerland.

 

About Medifirst Solutions, Inc.

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

______________________________

 

 

FOR IMMEDIATE RELEASE

Contact:          Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

 

 

MEDIFIRST SOLUTIONS ANNOUNCES SHAREHOLDER UPDATE

 

 

Freehold, NJ – December 8, 2017 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, presents an update and follow up after exhibiting at the Greater New York Dental Meeting. Additionally, the Company will discuss several new developments.

GREATER NEW YORK DENTAL MEETING
The Company presented its Infrared Laser at the Greater New York Dental Meeting held in the Jacob Javits Center which ended November 29th 2017. Commented Medifirst President Bruce J. Schoengood, “We are very pleased with the enthusiastic response from dentists, surgeons and various specialists regarding our laser and its applications. The Time Machine Laser has shown effective and immediate results for patients suffering from pain related to their temporomandibular joint (TMJ). We believe TMJ treatment provides Medifirst with a very strong, untapped, niche application for dental practitioners. With very few treatments available and great interest in our Infrared Laser, we have over two hundred interested parties requesting follow ups, meetings and demonstrations.” Dentistry professionals that we are engaging with include various practitioners, as well as distributors, TMJ treatment centers and a variety of specialists. Continued Schoengood, “One of our big takeaways was the tremendous opportunity to introduce lasers to dental professionals who have not yet incorporated laser technology into their practice. Over 90% of the doctors we met are just looking and learning at laser technology and being able to target laser usage for TMJ patients was of great interest.”

CHINA SALES AND DISTRIBUTION
Medifirst is pleased to announce that it has come to terms with a highly experienced organization to help commercialize the Time Machine Laser for the China market. Continued Mr. Schoengood, “This could be an exceptional opportunity for us to work with a company that is extremely experienced in the global medical device industry and especially the vast China market. The firm believes that our laser product can be commercialized in the global marketplace.” Management of this firm has extensive top-tier experience in pharma, bio-tech and bringing young companies to market. The Company anticipates completing a definitive agreement in the upcoming days and we will update shareholders upon successfully completing an agreement.  Medifirst anticipates that it will begin to file for CFDA (China FDA) clearance in the upcoming weeks or months.

R&D AND CERTIFICATIONS
Medifirst is pleased to announce that is has signed a non-binding Letter of Intent with a New Jersey technology company to explore developing blockchain based applications that can enhance the marketing and sales of the Time Machine Laser Series on the international marketplace. In addition, if the Company is successful in its immediate funding goals, it anticipates applying for FDA 510(k) Clearance for its Green (aesthetics) Laser as well as to apply for additional certifications in Europe, China and the US. Medifirst anticipates updates and announcements in the upcoming day and weeks.

About Medifirst Solutions, Inc.

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

 

--------------------------------------------------------------------------------------------------------------------------------------------------------------------

FOR IMMEDIATE RELEASE

Contact:          Investor Relations

Phone:             (732) 786-8044

Email:              admin@medifirstsolutions.com

Website:          www.medifirstsolutions.com

 

 

MEDIFIRST SOLUTIONS TO INTRODUCE THE TIME MACHINE LASER AT THE GREATER NEW YORK DENTAL MEETING AT THE JAVITS CONVENTION CENTER

 

Freehold, NJ – November 13, 2017 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce that it is exhibiting at the Greater New York Dental Meeting. A six-day event being held from November 24th to the 29th 2017 at the Jacob K. Javits Convention Center in New York City.

Commented Medifirst President Bruce J. Schoengood, “We are very pleased to be introducing our Laser in the biggest dental conference held in the country. The Time Machine Laser has shown exceptional and immediate results for patients who suffer from excruciating pain related to TMJ. The conference, with over 600 exhibitors, presents a wonderful opportunity to introduce our FDA cleared Time Machine Infrared Therapeutic Laser to the dental industry. We believe that the Time Machine Laser presents a targeted, natural, noninvasive and effective pain treatment option for patients who otherwise are reliant on drugs for immediate relief.  We will be exhibiting at Booth 1010 and we welcome everyone to come visit us.”

According to the Mayo clinic, the temporomandibular joint (TMJ) acts like a sliding hinge, connecting your jawbone to your skull. You have one joint on each side of your jaw. TMJ disorders — a type of temporomandibular disorder or TMD — can cause pain in your jaw joint and in the muscles that control jaw movement. The exact cause of a person's TMJ disorder is often difficult to determine. Your pain may be due to a combination of factors, such as genetics, arthritis or jaw injury. Some people who have jaw pain also tend to clench or grind their teeth, although many people habitually clench or grind their teeth and never develop TMJ disorders.

Commented Medifirst VP and Medical Director Dr. Ronald L. Rubin, “Knowing that TMJ patients feel significant pain reduction after their first visit using the laser treatment is simply wonderful for both doctors and patients.  It is exceptionally appealing to doctors’ practices because by simply using a non-invasive 100% natural energy treatment, their patients report immediate pain relief, as well as a decrease in muscle spasms within minutes. No drugs, no splints, no endless heat and no TENS therapy. I look forward to meeting everyone and introducing the Time Machine Laser at this spectacular dental conference.”

About Medifirst Solutions, Inc.

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 #  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

_________________________________________________________________________________________________________________________

FOR IMMEDIATE RELEASE

Contact:           Investor Relations
Phone:             (732) 786-8044
Email:              admin@medifirstsolutions.com
Website:          www.medifirstsolutions.com

 

 

MEDIFIRST SIGNS DISTRIBUTION AGREEMENT FOR MOROCCO

 

 

Freehold, NJ – August 31, 2017 – MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce that it has signed a distribution agreement with an international distribution company based in Morocco. The three year term of this Agreement grants the distributor exclusivity for the country of Morocco so long as the distributor meets aggregate sales of $375,000 USD.    

 

Commented Medifirst’s President, Bruce Schoengood, “Our first international presentation was in Morocco and we are very excited and pleased to be entering this market.  We continue to see a demand for new, non-addictive, natural and effective ways to treat people suffering from acute and chronic pain.  We are working with our distribution partner in Morocco to complete the device registration process, which we believe is almost complete, and we are confident we will be successful.”  No assurances can be made that the Company will be granted clearance to sell or, if clearance is achieved, that the distributor will be successful in its sales efforts.

 

Medifirst recently announced a distribution arrangement for Mid-East territories, including Lebanon, Kuwait, Saudi Arabia, United Arab of Emirates, Bahrain, Qatar, Oman, Jordan and Iraq. The Company is currently training and working with the distributors and their representatives as part of the introduction and roll-out process. Medifirst continues to receive strong interest for its product in China and, though no assurances can be made, it anticipates providing updates on the progress of these discussions in the upcoming days and weeks. The Company is working diligently to tackle the US market and it has added a number of consultants and sales representatives in the recent weeks. Additionally, Medifirst continues to offer the Time Machine Infrared Laser as part of its aggressive 30 day free trial, no strings attached program.  The Company also anticipates further updates on its US market efforts in the upcoming days and weeks.

About Medifirst Solutions, Inc.

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

 

#  #  #

Forward-Looking Statements:  

The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

____________________________________________________________________________________________________________________________

 

_________________________________________________________